Healthcare Services

Atrial Septal Defect Market Size Forecast To Achieve $6.26 Billion By 2030 With 6.8% CAGR

May 27, 2026June 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Atrial Septal Defect Market Between 2026 And 2030?

The atrial septal defect market has seen substantial growth in recent years. It is anticipated to increase from $4.46 billion in 2025 to $4.81 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. The expansion observed in prior periods can be attributed to enhanced detection of congenital heart defects, greater access to surgical correction techniques, the broadening of pediatric cardiology services, accumulating clinical experience with device-based closures, and more extensive access to diagnostic imaging technologies.

The atrial septal defect market is anticipated to witness robust expansion in the coming years, with its size projected to reach $6.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period is attributed to several factors, including the increasing adoption of hybrid closure techniques, a heightened focus on early intervention in adults, the expansion of minimally invasive cardiac surgery capabilities, ongoing innovation in occluder device design, and a rising demand for long-term follow-up care solutions. Key trends expected over the forecast period include the increasing use of transcatheter closure devices, a growing preference for minimally invasive repair procedures, the expanding application of advanced cardiac imaging techniques, the proliferation of pediatric and adult asd screening programs, and an enhanced emphasis on long-term patient outcomes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16345&type=smp

Which Drivers Are Advancing The Atrial Septal Defect Market Growth?

The rising occurrence of congenital heart defects (CHD) is projected to fuel the expansion of the atrial septal defect market in the future. These defects are defined as structural anomalies within the heart that are evident from birth, with the increasing prevalence referring to the growing number of individuals identified with these birth-present structural heart abnormalities. Treatment for atrial septal defects addresses congenital heart defects by rectifying irregular blood circulation between the heart’s compartments, thereby enhancing overall heart performance and mitigating related issues. For example, in September 2025, the British Heart Foundation, a UK non-profit, reported that 2.3 million people in the UK are affected by congenital heart disease. Moreover, congenital heart disease defects are detected in a minimum of 1 in 150 births, averaging 13 babies daily in the UK, with additional diagnoses occurring later in life. Projections indicate that up to 1-2 percent of the populace could be impacted. Consequently, the widespread occurrence of congenital heart defects is anticipated to propel the atrial septal defect market.

How Is The Atrial Septal Defect Market Distributed Across Key Segments?

The atrial septal defect market covered in this report is segmented –

1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy

2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry

3) By Product Type: Medical Devices, Pharmaceutical Products

4) By Age Group: Pediatric, Adult

5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users

Subsegments:

1) By Surgical Closure: Open Heart Surgery (Traditional Surgical Closure), Minimally Invasive Surgical Closure, Patches (Pericardial, Synthetic) For Asd Closure

2) By Transcatheter Closure: Device-Based Closure (Amplatzer Septal Occluder), Transcatheter Plug Closure Techniques, Catheter-Based Asd Repair For Adult And Pediatric Patients

3) By Hybrid Procedures: Combination Of Surgical And Transcatheter Techniques, Minimally Invasive Hybrid Procedures, Hybrid Closure For Complex Or Large Asds

4) By Medication Therapy: Anticoagulant Therapy (To Prevent Stroke), Diuretics (For Managing Symptoms), Antihypertensive Drugs (For Managing Associated Conditions), Off-Label Use Of Other Medications

Which Trends Are Supporting The Evolution Of The Atrial Septal Defect Market?

Leading companies in the arterial septal defect market are developing advanced devices and seeking regulatory approval to expand their availability and utility. Device approval entails obtaining official authorization or certification for a device, typically from a regulatory body or relevant authority, before it can be legally manufactured, sold, or employed in a specific market or for a particular purpose. For instance, in March 2024, Occlutech GmbH, a Sweden-based specialist provider of minimally invasive cardiac devices, announced that the United States Food and Drug Administration (FDA) had approved the Occlutech ASD Occluder and Occlutech Pistol Pusher for treating atrial septal defects (ASD). This approval signifies a major achievement for the company, which has been committed to advancing healthcare globally. The Occlutech ASD Occluder is designed to serve as a lifelong solution for patients with echocardiography-confirmed defects. It is a self-expanding nitinol device that incorporates two flexible discs attached to both sides of the patient’s atrial septum using the Occlutech Pistol Pusher. With this authorization, Occlutech will initiate commercialization in the US through an exclusive partnership with B. Braun Interventional Systems.

Which Key Players Are Active In The Atrial Septal Defect Market?

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Osypka AG, Cardia Inc, Gore Medical, Pfm Medical AG, Balton Sp. z o.o., Meril Life Sciences, TTK Healthcare, Braile Biomedica, Shanghai Shape Memory Alloy

Access The Complete Atrial Septal Defect Market Report:

https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

Which Region Commands The Largest Share Of The Atrial Septal Defect Market?

North America was the largest region in the atrial septal defect market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Atrial Septal Defect Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16345&type=smp

Browse Through More Reports Similar to the Global Atrial Septal Defect Market 2026, By The Business Research Company

Left Atrial Appendage Closure Device Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/left-atrial-appendage-closure-device-global-market-report

Atrial Fibrillation Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrial-fibrillation-global-market-report

Congenital Heart Defect Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795